Elotuzumab-mediated ADCC with Th1-like Vγ9Vδ2 T cells to disrupt myeloma-osteoclast interaction.
Inoue Y, Tenshin H, Teramachi J, Sumitani R, Oda A, Maeda Y, Oura M, Sogabe K, Maruhashi T, Takahashi M, Fujii S, Nakamura S, Miki H, Hara T, Endo I, Kagawa K, Ozaki S, Hiasa M, Harada T, Abe M.
Inoue Y, et al. Among authors: ozaki s.
Cancer Sci. 2024 Nov 18. doi: 10.1111/cas.16401. Online ahead of print.
Cancer Sci. 2024.
PMID: 39557586
Free article.